| (Values in U.S. Thousands) | Sep, 2020 | Sep, 2019 | Sep, 2018 | Sep, 2017 | Sep, 2016 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | -100.00% |
| Net Income | -540 | -680 | -820 | -1,680 | -3,500 |
| Net Income Growth | +20.59% | +17.07% | +51.19% | +52.00% | -221.10% |
Angiosoma Inc (SOAN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
AngioSoma, Inc. is a biotechnology company. It focused on improving endovascular interventions in the treatment of peripheral artery disease. The Company's product candidate consists of Liprostin (TM) which is in preclinical trial stage. AngioSoma, Inc., formerly known as First Titan Corp., is based in HOUSTON, TX.